Comparative Pharmacology
Head-to-head clinical analysis: NEXLETOL versus NEXLIZET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXLETOL versus NEXLIZET.
NEXLETOL vs NEXLIZET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits microsomal triglyceride transfer protein (MTP), thereby reducing the hepatic secretion of apolipoprotein B-containing lipoproteins including LDL and VLDL.
Bempedoic acid inhibits ATP-citrate lyase, reducing cholesterol synthesis; ezetimibe inhibits intestinal cholesterol absorption via NPC1L1 blockade.
240 mg orally once daily (two 120 mg tablets) with or without food. Do not break, crush, or chew tablets.
Bempedoic acid 180 mg and ezetimibe 10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 15 to 20 hours. Steady-state reached within 2 to 4 weeks.
Bempedoic acid: 15–24 hours (terminal); ezetimibe: 22 hours (terminal) for ezetimibe-glucuronide, with clinical steady-state achieved within 3–5 days.
Primarily hepatic metabolism followed by biliary excretion into feces. <2% excreted unchanged in urine.
Bempedoic acid: ~70% renal (unchanged and as glucuronide conjugate), ~30% fecal; ezetimibe: primarily fecal (78%) and renal (11%) after enterohepatic recycling.
Category C
Category C
Lipid-Lowering Agent
Lipid-Lowering Agent